Extending Our Knowledge of Lifetime Outcomes After ST-Elevation Myocardial Infarction

In the extended follow-up of the Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction (EXAMINATION) trial, Arévalos et al 1 Arévalos V Spione F Gabani R Ortega-Paz L Gómez-Lara J Jiménez-Díaz V Jiménez M Jiménez-Quevedo P Diletti R Pineda J Campo G Silvestro A Maristany J Flores X Oyarzabal L Bastos-Fernandez G Iñiguez A Serra A Escaned J Ielasi A Tespili M Lenzen M Fernández-Ortiz A Bordes P Tebaldi M Biscaglia S Al-Shaibani S Romaguera R Gómez-Hospital JA Rodes-Cabau J Serruys PW Sabaté M Brugaletta S. Impact of age at the time of the first ST-Elevation myocardial infarction on 10-year outcomes (from the EXAMINATION EXTEND trial). Am J Cardiol. 2022; 190: 32-40 Abstract Full Text Full Text PDF PubMed Scopus (1) Google Scholar describe the age-related outcomes in a cohort of patients with ST-elevation myocardial infarction (STEMI). The primary aim of this trial was to study the impact of drug-eluting stents (DES; everolimus) versus that of bare-metal stents (BMS) in patients with early presentation of STEMI. This was an all-comer, multicenter, prospective, randomized, 2-arm, single-blind, controlled trial conducted at 12 academic hospital centers in 3 European countries. In the initial, nearly 1,500 patients cohort, this study showed the superiority of DES over BMS at 5 years and was subsequently lengthened to 10 years in the EXAMINATION-EXTEND. This particular substudy of 1,375 patients aimed to assess 10-year patient-oriented composite end point of all-cause death, any myocardial infarction (MI), or any revascularization after STEMI, when stratified by age into 4 groups: <55, 55 to 65, 65 to 75, and >75 years. 1 Arévalos V Spione F Gabani R Ortega-Paz L Gómez-Lara J Jiménez-Díaz V Jiménez M Jiménez-Quevedo P Diletti R Pineda J Campo G Silvestro A Maristany J Flores X Oyarzabal L Bastos-Fernandez G Iñiguez A Serra A Escaned J Ielasi A Tespili M Lenzen M Fernández-Ortiz A Bordes P Tebaldi M Biscaglia S Al-Shaibani S Romaguera R Gómez-Hospital JA Rodes-Cabau J Serruys PW Sabaté M Brugaletta S. Impact of age at the time of the first ST-Elevation myocardial infarction on 10-year outcomes (from the EXAMINATION EXTEND trial). Am J Cardiol. 2022; 190: 32-40 Abstract Full Text Full Text PDF PubMed Scopus (1) Google Scholar Importantly, patients with previous coronary artery disease (CAD) were excluded from this analysis because those patients were correctly considered at higher risk for repeat events in such an extended follow-up. Impact of Age at the Time of the First ST-Elevation Myocardial Infarction on 10-Year Outcomes (from the EXAMINATION-EXTEND Trial)American Journal of CardiologyVol. 190PreviewThe aim of this substudy of the EXAMINATION-EXTEND was to analyze 10-year outcomes according to the patient's age at the time of the first ST-elevation myocardial infarction (STEMI). Of 1,498 patients with STEMI included in the EXAMINATION-EXTEND study, those with a previous history of coronary ischemic even or ischemic stroke were excluded from this analysis. The remaining 1,375 patients were divided into 4 age groups: <55, 55 to 65, 65 to 75, and >75 years. The primary end point was 10-year patient-oriented composite end point (POCE) of all-cause death, any MI, or any revascularization. Full-Text PDF